gptkbp:instanceOf
|
gptkb:cancer
|
gptkbp:accountsFor
|
about 15% of lung cancers
|
gptkbp:alsoKnownAs
|
gptkb:SCLC
|
gptkbp:cause
|
gptkb:Lambert-Eaton_myasthenic_syndrome
gptkb:paraneoplastic_syndromes
gptkb:Cushing_syndrome
gptkb:SIADH
|
gptkbp:characterizedBy
|
rapid growth
early metastasis
|
gptkbp:commonIn
|
older adults
smokers
|
gptkbp:detects
|
gptkb:chest_X-ray
gptkb:CT_scan
MRI
PET scan
|
gptkbp:diagnosedBy
|
imaging
biopsy
|
gptkbp:expressedIn
|
neuroendocrine markers
|
gptkbp:firstDescribed
|
1926
|
gptkbp:hasHigh
|
necrosis
mitotic rate
|
gptkbp:hasPoorerPrognosisThan
|
gptkb:non-small_cell_lung_cancer
|
https://www.w3.org/2000/01/rdf-schema#label
|
Small cell lung cancer
|
gptkbp:ICD-10_code
|
C34
|
gptkbp:MeSH_ID
|
D002289
|
gptkbp:mostCommonRiskFactor
|
tobacco smoking
|
gptkbp:originatedIn
|
lung epithelial cells
|
gptkbp:prognosis
|
poor
|
gptkbp:rareIn
|
non-smokers
|
gptkbp:stagedBy
|
extensive stage
limited stage
|
gptkbp:subspecies
|
combined small cell carcinoma
small cell carcinoma
|
gptkbp:symptom
|
weight loss
cough
chest pain
dyspnea
|
gptkbp:treatment
|
gptkb:durvalumab
gptkb:atezolizumab
gptkb:carboplatin
gptkb:irinotecan
gptkb:topotecan
gptkb:cisplatin
radiation therapy
chemotherapy
immunotherapy
antineoplastic agent
surgery (rarely)
|
gptkbp:bfsParent
|
gptkb:Neuroendocrine_Tumor
|
gptkbp:bfsLayer
|
6
|